Incyte Corp

Research Incyte Corp (INCY) on Bullrun: valuation model: 22.6% undervalued, market cap USD 22.91B, P/E 16.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerINCY
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal22.6% undervalued
• Market capUSD 22.91B
• P/E16.2
• Financial periodFY2025
• RevenueUSD 5.14B
• Revenue growth21.2%
• Net incomeUSD 1.29B
• Gross margin92.8%

Valuation Snapshot

Bullrun's latest valuation model marks Incyte Corp as 22.6% undervalued; latest market cap is USD 22.91B; P/E is 16.2.

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia;

Frequently asked questions

Is Incyte Corp overvalued or undervalued?

Bullrun's valuation model currently marks Incyte Corp as 22.6% undervalued.

What is Incyte Corp's market cap?

Incyte Corp's market capitalization is USD 22.91B.

What is Incyte Corp's P/E ratio?

Incyte Corp's price-to-earnings (P/E) ratio is 16.2.

What does Incyte Corp do?

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.